Contract services company Aptuit will invest $1 million in its facility in Glasgow, Scotland, to expand its capacity to manufacture sterile cytotoxic liquid and lyophilized drug products. The company expects the new equipment to be operating sometime next year. David Stevens, the company's senior director and site head at Aptuit Glasgow, said in a statement: "It is expected that biopharmas will be increasing their cytotoxic injectable outsourcing over the next few years, driven by the robust demand for oncology and other high potency drugs such as Antibody Drug Conjugates (ADCs) and IV fluids requiring a quick onset of action." A number of contract manufacturers have been expanding ther ADC and cytotoxic capabilities in anticipation of this growth. Release | More